Jess G. Fiedorowicz

University of Ottawa

2 papers in the library · 13 citations · publishing 2025

Papers

Psilocybin Dispensaries and Online Health Claims in Canada

JAMA Network Open April 1, 2025 Jenna Matsukubo, Sarah Dickson, Jennifer Xiao et al. 7 citations

As of May 2024, 57 psilocybin dispensaries operated in Canada, located in 15 of 42 major cities (35.7%) and concentrated in Ontario and British Columbia. Most stores (61.4%) were part of a chain, 91.2% had an online presence, and all sold dried mushrooms, with many also offering microdosing capsules, chocolates, and gummies. 65.2% sold products mimicking popular food brands. Among stores with websites, 86.4% claimed mental health benefits such as alleviating anxiety, yet warnings about driving, pregnancy, or history of psychosis were rare (9.1%, 13.6%, and 31.8% respectively). The findings suggest a need for greater regulatory measures to protect the public.

DOI: 10.1001/jamanetworkopen.2025.2853 Psilocybin Dispensary Business Advertising +4

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis

Therapeutic Advances in Psychopharmacology September 1, 2025 Stanley Wong, Gray Meckling, Nicholas Fabiano et al. 6 citations

A systematic review and meta-analysis of nine randomized controlled trials involving 593 adults with psychiatric diagnoses found that psilocybin therapy led to a small but significant decrease in suicidal ideation compared to control conditions. No studies reported suicide attempts or deaths. The analysis showed low heterogeneity and no publication bias, though two studies had a high risk of bias. Current evidence is limited by small sample sizes, insufficient follow-up data, and inadequate assessment of blinding.

DOI: 10.1177/20451253251372449